Healthcare Industry News: NIBP
News Release - October 15, 2010
Cheetah Medical Announces European Launch of a New NICOM(R) System for Advanced Noninvasive Hemodynamic Monitoring and Fluid Management
Cheetah's Noninvasive Hemodynamic Monitoring System now Available With Integrated Pulse Oxymetry and Oxygen Delivery Functionality to Expedite Fluid Optimization, Goal-Directed Therapy and Comprehensive Hemodynamic ManagementTEL AVIV, Israel, October 15, 2010 -- (Healthcare Sales & Marketing Network) -- Cheetah Medical today announced the European launch of its new NICOM(R) System which offers an integrated Pulse Oximetry functionality (OxiMax(R) Covidien plc). In addition to core hemodynamic parameters including Cardiac Output (CO), Stroke Volume (SV), Noninvasive Blood Pressure (NIBP), Total Peripheral Resistance (TPR) and Stroke Volume Variation (SVV), the new system provides a new important parameter, Oxygen Delivery Index (DO2I).
DO2I is a key indicator of oxygen delivery to the organs and tissues which is increasingly used to guide crucial resuscitation decisions in septic, surgical and other critically ill patients. It is a product of the amount of blood supplied to the tissues, also known as Cardiac Output and the blood oxygen content. In addition, the NICOM 3.0 now offers a user friendly, intuitive touch-screen and real-time event-marking to enable rapid onset of monitoring and has interfacing capabilities with hospital monitoring and electronic systems.
Daniel Burkhoff, M.D., Ph.D., Medical Director of Cheetah Medical and a leading clinical researcher in the field of heart failure said: "Accurate continuous hemodynamic monitoring to guide decisions on fluid management and drug titration is quickly becoming a vital component of treatment of the most common life-threatening conditions, including sepsis, heart failure and high-risk surgery. The addition of Oxygen Delivery Index provides clinicians with yet another previously validated important parameter that can be used to implement up-to-date goal directed resuscitation approaches."
Yoav Avidor MD, CEO of Cheetah Medical added: "With the increase in prevalence of sepsis, heart failure and major surgical procedures and the awareness for the pivotal role of fluid resuscitation in outcomes and costs, hospitals are looking for accurate and practical technologies that help tailor fluids and hemodynamic drugs to patient's vital signs. With added Pulse Oximetry and DO2I functionality Cheetah's NICOM now empowers physicians and nurses with a comprehensive suite of information for fluid management in critically ill patients, all in 100% noninvasive fashion. Our goal is to help providers to keep in line with contemporary, cutting edge care without the need for legacy invasive instrumentation and help clear the way for significant expansion of critical treatments to more patients and sites of care."
About Cheetah Medical
Cheetah Medical's NICOM(R) Noninvasive Cardiac Output and Hemodynamic Monitoring System uses the company's proprietary BIOREACTANCE(R) Technology to deliver continuous, accurate, noninvasive cardiac output (CO) and other vital hemodynamic monitoring parameters. The system is US FDA cleared and CE Marked, and since its commercial launch in 2008 has been adopted by a growing number of clinicians worldwide. Cheetah Medical headquarters is located in Tel-Aviv, Israel and its United States headquarters is located in Portland, Oregon. For more information, visit our website at http://www.cheetah-medical.com.
Source: Cheetah Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
